Method for predicting sensitivity of cancer cell to gpx4 inhibitor
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsKiyomoto Ogasawara, Keisuke Hashimoto, Kenji Kashima, Hiroshi Sakamoto
Life of this patent
Estimating the term…
Abstract
Provided are a cancer therapeutic drug comprising a compound which inhibits GPX4 as an active ingredient, the cancer therapeutic drug treating cancer containing a cancer cell having a suppressed function of a SWI/SNF complex factor detected; and a method for predicting sensitivity of a cancer cell to a GPX4 inhibitor, the method comprising the step of predicting a cancer cell having a suppressed function of a SWI/SNF complex factor detected in the cancer cell, as having sensitivity to the GPX4 inhibitor.
Claims20
1-17. (canceled)
A method of treating cancer in a patient, the method comprising
- identifying, or having identified, a patient as having a cancer comprising a cancer cell exhibiting decreased activity of a SWI/SNF complex factor compared to the SWI/SNF complex factor’s activity in a normal control cell;
- and
- administering to the patient a compound that inhibits glutathione peroxidase 4 (GPX4).
A method of treating cancer in a patient, the method comprising
- identifying, or having identified, a patient as having a cancer comprising a cancer cell that has a loss-of-function mutation in a gene encoding a SWI/SNF complex factor;
- and
- administering to the patient a compound that inhibits glutathione peroxidase 4 (GPX4).
A method of treating cancer in a patient, the method comprising
- determining, or having determined, that the patient comprises a gene encoding a SWI/SNF complex factor that has a loss-of-function mutation;
- and
- administering to the patient a compound that inhibits GPX4.
A method of selecting a cancer treatment for a patient, the method comprising
- assaying, or having assayed, an activity of a SWI/SNF complex factor in a sample of cancer cells obtained from the patient;
- determining that the activity of the SWI/SNF complex factor in the cancer cells is decreased compared to the activity of the SWI/SNF complex in a normal control cell;
- and
- selecting a cancer treatment for the patient, wherein the treatment comprises administering a compound that inhibits GPX4.
A method of identifying a compound for use in treating cancer, the method comprising:
- selecting a compound that inhibits GPX4;
- providing a cancer cell in which an activity of a SWI/SNF complex factor is decreased compared to the activity of the SWI/SNF complex factor in a normal control cell;
- assaying the compound’s ability to inhibit growth of the cancer cell, thereby determining that the compound inhibits growth of the cancer cell;
- and
- identifying the compound as potentially useful for treating cancers characterized as having decreased activity of the SWI/SNF complex factor.
Dependencies are inferred from the claim text.